Hematide, peginesatide    (DrugBank: Peginesatide, Hematide)

1 disease
IDDisease name (Link within this page)Number of trials
283Acquired pure red cell aplasia1

283. Acquired pure red cell aplasia    [ 17 clinical trials,   36 drugs,   (DrugBank: 19 drugs),   16 drug target genes,   91 drug target pathways]
Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 17 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-004944-30-DE
(EUCTR)
08/03/200620/12/2005A Phase 2 study of AF37702 Injection for anemia in patients with pure red cell aplasia.An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection (Hematideā„¢) in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease - AFX01-06 Anemia caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease
MedDRA version: 18.0;Level: PT;Classification code 10002965;Term: Aplasia pure red cell;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: AF37702 Injection
Product Code: AF37702, Hematide
INN or Proposed INN: peginesatide
Other descriptive name: Hematide, peginesatide
Product Name: AF37702 Injection
Product Code: AF37702, Hematide
INN or Proposed INN: peginesatide
Other descriptive name: Hematide, peginesatide
Takeda Development Centre Europe LtdNULLNot RecruitingFemale: yes
Male: yes
40Phase 2Germany;United Kingdom